These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
476 related articles for article (PubMed ID: 32450105)
1. Membrane-core nanoparticles for cancer nanomedicine. Guo J; Huang L Adv Drug Deliv Rev; 2020; 156():23-39. PubMed ID: 32450105 [TBL] [Abstract][Full Text] [Related]
2. Nanomedicines Targeting the Tumor Microenvironment. Tong R; Langer R Cancer J; 2015; 21(4):314-21. PubMed ID: 26222084 [TBL] [Abstract][Full Text] [Related]
3. Emergence in protein derived nanomedicine as anticancer therapeutics: More than a tour de force. Wang Z; Zhi K; Ding Z; Sun Y; Li S; Li M; Pu K; Zou J Semin Cancer Biol; 2021 Feb; 69():77-90. PubMed ID: 31962173 [TBL] [Abstract][Full Text] [Related]
4. Challenges and pitfalls in the development of liposomal delivery systems for cancer therapy. Moosavian SA; Bianconi V; Pirro M; Sahebkar A Semin Cancer Biol; 2021 Feb; 69():337-348. PubMed ID: 31585213 [TBL] [Abstract][Full Text] [Related]
5. Update on Nanotechnology-based Drug Delivery Systems in Cancer Treatment. Ho BN; Pfeffer CM; Singh ATK Anticancer Res; 2017 Nov; 37(11):5975-5981. PubMed ID: 29061776 [TBL] [Abstract][Full Text] [Related]
6. Recent advances in "smart" delivery systems for extended drug release in cancer therapy. Kalaydina RV; Bajwa K; Qorri B; Decarlo A; Szewczuk MR Int J Nanomedicine; 2018; 13():4727-4745. PubMed ID: 30154657 [TBL] [Abstract][Full Text] [Related]
7. Size shrinkable drug delivery nanosystems and priming the tumor microenvironment for deep intratumoral penetration of nanoparticles. Niu Y; Zhu J; Li Y; Shi H; Gong Y; Li R; Huo Q; Ma T; Liu Y J Control Release; 2018 May; 277():35-47. PubMed ID: 29545106 [TBL] [Abstract][Full Text] [Related]
8. Nanomedicine: Innovative Strategies and Recent Advances in Targeted Cancer Therapy. Gautam RK; Mittal P; Goyal R; Dua K; Mishra DK; Sharma S; Singla RK Curr Med Chem; 2024; 31(28):4479-4494. PubMed ID: 37828674 [TBL] [Abstract][Full Text] [Related]
9. Factors Influencing the Delivery Efficiency of Cancer Nanomedicines. Ullah R; Wazir J; Khan FU; Diallo MT; Ihsan AU; Mikrani R; Aquib M; Zhou X AAPS PharmSciTech; 2020 May; 21(4):132. PubMed ID: 32409932 [TBL] [Abstract][Full Text] [Related]
11. Nanomaterials multifunctional behavior for enlightened cancer therapeutics. Raju GSR; Dariya B; Mungamuri SK; Chalikonda G; Kang SM; Khan IN; Sushma PS; Nagaraju GP; Pavitra E; Han YK Semin Cancer Biol; 2021 Feb; 69():178-189. PubMed ID: 31419527 [TBL] [Abstract][Full Text] [Related]
12. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy. Pérez-Herrero E; Fernández-Medarde A Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885 [TBL] [Abstract][Full Text] [Related]
13. Implications of nanotechnology for the treatment of cancer: Recent advances. Klochkov SG; Neganova ME; Nikolenko VN; Chen K; Somasundaram SG; Kirkland CE; Aliev G Semin Cancer Biol; 2021 Feb; 69():190-199. PubMed ID: 31446004 [TBL] [Abstract][Full Text] [Related]
14. Novel Strategies for Disrupting Cancer-Cell Functions with Mitochondria-Targeted Antitumor Drug-Loaded Nanoformulations. S Allemailem K; Almatroudi A; Alsahli MA; Aljaghwani A; M El-Kady A; Rahmani AH; Khan AA Int J Nanomedicine; 2021; 16():3907-3936. PubMed ID: 34135584 [TBL] [Abstract][Full Text] [Related]
15. Therapeutic nanoparticles for drug delivery in cancer. Cho K; Wang X; Nie S; Chen ZG; Shin DM Clin Cancer Res; 2008 Mar; 14(5):1310-6. PubMed ID: 18316549 [TBL] [Abstract][Full Text] [Related]
16. Nanostructured Systems for the Organelle-specific Delivery of Anticancer Drugs. Joanitti GA; Ganassin R; Rodrigues MC; Figueiro Longo JP; Jiang CS; Gu J; Leal Pinto SM; Almeida Dos Santos MF; de Azevedo RB; Muehlmann LA Mini Rev Med Chem; 2017; 17(3):224-236. PubMed ID: 27739361 [TBL] [Abstract][Full Text] [Related]
17. How nanotechnology can enhance docetaxel therapy. Zhang L; Zhang N Int J Nanomedicine; 2013; 8():2927-41. PubMed ID: 23950643 [TBL] [Abstract][Full Text] [Related]
18. The EPR effect and beyond: Strategies to improve tumor targeting and cancer nanomedicine treatment efficacy. Shi Y; van der Meel R; Chen X; Lammers T Theranostics; 2020; 10(17):7921-7924. PubMed ID: 32685029 [TBL] [Abstract][Full Text] [Related]
19. DePEGylation strategies to increase cancer nanomedicine efficacy. Kong L; Campbell F; Kros A Nanoscale Horiz; 2019 Mar; 4(2):378-387. PubMed ID: 32254090 [TBL] [Abstract][Full Text] [Related]
20. Preface: Nanoformulations for combination or cascade anticancer therapy. Zhang Q; Huang L Adv Drug Deliv Rev; 2017 Jun; 115():1-2. PubMed ID: 28887913 [No Abstract] [Full Text] [Related] [Next] [New Search]